Supernus Pharmaceuticals Inc
$ 44.41
-2.50%
12 Jun - close price
- Market Cap 2,577,544,000 USD
- Current Price $ 44.41
- High / Low $ 45.71 / 44.16
- Stock P/E N/A
- Book Value 18.48
- EPS -0.51
- Next Earning Report 2026-08-04
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA 0.01 %
- ROE -0.03 %
- 52 Week High 59.68
- 52 Week Low 30.83
About
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of diseases of the central nervous system in the United States. The company is headquartered in Rockville, Maryland.
Analyst Target Price
$62.83
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-05 | 2026-02-24 | 2025-11-04 | 2025-08-05 | 2025-05-06 | 2025-02-25 | 2024-11-04 | 2024-08-06 | 2024-05-08 | 2024-02-27 | 2023-11-08 | 2023-08-08 |
| Reported EPS | 0.21 | 0.8821 | 0.61 | 0.91 | -0.21 | 0.5483 | 1.1 | 0.67 | 0.24 | 0.89 | 0.24 | 0.49 |
| Estimated EPS | 0.28 | 0.41 | 0.82 | 0.47 | 0.03 | 0.52 | 0.44 | 0.39 | 0.38 | 0.55 | 0.08 | 0.21 |
| Surprise | -0.07 | 0.4721 | -0.21 | 0.44 | -0.24 | 0.0283 | 0.66 | 0.28 | -0.14 | 0.34 | 0.16 | 0.28 |
| Surprise Percentage | -25% | 115.1463% | -25.6098% | 93.617% | -800% | 5.4423% | 150% | 71.7949% | -36.8421% | 61.8182% | 200% | 133.3333% |
Next Quarterly Earnings
| Jun 2026 | |
|---|---|
| Reported Date | 2026-08-04 |
| Fiscal Date Ending | 2026-06-30 |
| Estimated EPS | 0.3 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: SUPN
2026-06-07 01:11:00
This article provides an algorithmic analysis of Supernus Pharmaceuticals Inc. (NASDAQ: SUPN), indicating weak near and mid-term sentiment but a strong long-term outlook. It presents various AI-generated trading strategies including position trading, momentum, and risk hedging, along with multi-timeframe signal analysis for support and resistance levels. The report highlights elevated downside risk due to a lack of additional long-term support signals.
2026-06-05 09:10:44
This article reports that Supernus Pharmaceuticals (SUPN) has seen its average price target increased by 32.88% to $59.36. This updated target indicates a positive outlook from analysts regarding the company's future stock performance.
2026-06-04 10:10:16
This article reports that the price target for Supernus Pharmaceuticals (SUPN) has been increased by 32.88%, reaching $59.36. No further details are provided regarding the reasons for this adjustment or the analysts involved.
2026-05-28 04:38:50
Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN) announced its participation in two upcoming investor conferences in June 2026: the Jefferies Global Healthcare Conference and the Goldman Sachs 47th Annual Global Healthcare Conference. Management will engage in a fireside chat at the Jefferies conference, with a live audio webcast available, and investors can arrange meetings with the company at both events. Supernus Pharmaceuticals specializes in developing and commercializing treatments for central nervous system (CNS) diseases.
2026-05-27 20:39:40
Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN) announced its management will participate in two June investor conferences: the 2026 Jefferies Global Healthcare Conference on June 3, 2026, and the Goldman Sachs 47th Annual Global Healthcare Conference on June 8, 2026. The company, focused on CNS diseases, encourages investors to contact conference coordinators for meetings, with a webcast available for the Jefferies event.
2026-05-27 00:30:00
This article analyzes Supernus Pharmaceuticals Inc. (NASDAQ: SUPN) using AI models, identifying neutral near and mid-term sentiment but a positive long-term bias. It outlines three trading strategies—Position, Momentum Breakout, and Risk Hedging—with specific entry, target, and stop-loss zones. The analysis also highlights elevated downside risk due to a lack of additional long-term support signals.
